Praxis Precision Medicine received FDA Breakthrough Therapy Designation for elsunersen to treat SCN2A-DEE, a rare infant-onset epilepsy. Positive EMBRAVE Part A topline results and EMBRAVE3's single-arm design support a faster regulatory path, with durable seizure reductions and broader functional improvements observed. This milestone could accelerate approval timing and lift potential upside for PRAX if ongoing results remain favorable.
Praxis Precision Medicines reported POWER1 results for vormatrigine in focal onset seizures. The primary endpoint was not met, but the higher-dose arm showed a stronger seizure reduction and low discontinuations. Praxis is pausing POWER2 to reassess the program, while continuing focus on relutrigine and ulixacaltamide launches; about 90% of Vormatrigine patients moved to an open-label extension, signaling retention but uncertain path to approval.
Praxis has announced significant results from its trial of elsunersen, showing a notable 77% placebo-adjusted seizure reduction in pediatric patients with SCN2A developmental and epileptic encephalopathy. The positive safety profile and sustained efficacy could drive upcoming interest in this treatment as additional results are released at future conferences.
Praxis Precision Medicines, Inc. reported a larger-than-expected loss in Q4, which could raise concerns among investors about the company's financial health and future prospects. This unexpected downturn might lead to increased volatility in PRAX's stock price as investors reassess the company's potential and financial strategies.
PRAX stock surged after positive EMBOLD study results for relutrigine. The FDA will review data and decide on NDA filing soon. Analysts see relutrigine's peak sales potential rising to $2.8 billion. HC Wainwright raises the probability of success for relutrigine to 80%. Praxis expects NDA submission completion by early 2026.
